Wang Qiying, Wang Ximei, Zhai Xiaomei, Zhang Jianwen, Chen Minjing, Liu Linbo
Department of Plastic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.
Department of Plastic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China. Email:
Chin Med J (Engl). 2014;127(7):1339-43.
Melanoma has the highest mortality among all superficial malignant tumors. The poor prognosis is due to its high metastasis rate and the lack of therapeutic targets. As a molecular switch that controls tumor metastasis, Ras homology C (RhoC) has been correlated with tumor progression, especially tumor invasion and metastasis. However, little research has been done about the effects of RNA interference (RNAi) targeting RhoC on the invasion and metastasis of melanoma. In this study, we constructed an RNAi lentivirus vector targeting the RhoC gene of melanoma cells and identified its silencing effects on the RhoC gene.
Based on the RhoC gene encoding information, three pGPU6/GFP/Neo-short hairpin (shRNA) plasmids were constructed. After detecting their silencing effects on the RhoC gene of A375 cells, the most effective pGPU6/GFP/Neo-shRNA plasmid was packed with lentivirus to construct the recombinant pLenti6.3-EGFP-453 targeting RhoC. The lentivirus vector was used to infect A375 cells, and then the expression of RhoC mRNA and protein were determined with real-time PCR and Western blotting.
The plasmids pGPU6/GFP/Neo-shRNA 336, pGPU6/GFP/Neo-shRNA 453, and pGPU6/GFP/Neo-shRNA 680 were constructed. After they were transfected into A375 cells, the expressions of RhoC mRNA and protein were 1.47 ± 0.26, 1.13 ± 0.16, 1.39 ± 0.11 and 70.98 ± 9.21, 50.67 ± 6.06, 65.77 ± 4.06, respectively. pGPU6/GFP/Neo-shRNA 453 was the most effective sequence, and was used to successfully construct the pLenti6.3-EGFP-453 lentiviral vector targeting RhoC. pLenti6.3-EGFP-453 was used to infect A375 cells. The expression of RhoC mRNA and protein were 1.05 ± 0.05 and 62.04 ± 15.86 in the lentivirus group, 4.21 ± 0.24 and 220.86 ± 24.07 in the negative lentivirus control group, and 4.63 ± 0.32 and 257.39 ± 12.30 in the normal control group respectively with the difference between the lentivirus group and the control groups being statistically significant (P < 0.05).
The successfully constructed pLenti6.3-EGFP-453 vector targeting the RhoC can effectively infect human melanoma A375 cells in vitro, and significantly inhibit the RhoC mRNA and protein expression.
黑色素瘤在所有浅表恶性肿瘤中死亡率最高。其预后较差是由于高转移率以及缺乏治疗靶点。作为控制肿瘤转移的分子开关,Ras同源C(RhoC)与肿瘤进展相关,尤其是肿瘤侵袭和转移。然而,关于靶向RhoC的RNA干扰(RNAi)对黑色素瘤侵袭和转移影响的研究较少。在本研究中,我们构建了靶向黑色素瘤细胞RhoC基因的RNAi慢病毒载体,并鉴定了其对RhoC基因的沉默作用。
根据RhoC基因编码信息,构建了三种pGPU6/GFP/Neo-短发夹RNA(shRNA)质粒。检测它们对A375细胞RhoC基因的沉默作用后,将最有效的pGPU6/GFP/Neo-shRNA质粒包装成慢病毒,构建靶向RhoC的重组pLenti6.3-EGFP-453。用慢病毒载体感染A375细胞,然后通过实时PCR和蛋白质印迹法测定RhoC mRNA和蛋白质的表达。
构建了质粒pGPU6/GFP/Neo-shRNA 336、pGPU6/GFP/Neo-shRNA 453和pGPU6/GFP/Neo-shRNA 680。将它们转染到A375细胞后,RhoC mRNA和蛋白质的表达分别为1.47±0.26、1.13±0.16、1.39±0.11和70.98±9.21、50.67±6.06、65.77±4.06。pGPU6/GFP/Neo-shRNA 453是最有效的序列,用于成功构建靶向RhoC的pLenti6.3-EGFP-453慢病毒载体。用pLenti6.3-EGFP-453感染A375细胞。慢病毒组中RhoC mRNA和蛋白质的表达分别为1.05±0.05和62.04±15.86,阴性慢病毒对照组分别为4.21±0.24和220.86±24.07,正常对照组分别为4.63±0.32和257.39±12.30,慢病毒组与对照组之间的差异具有统计学意义(P<0.05)。
成功构建的靶向RhoC的pLenti6.3-EGFP-453载体可在体外有效感染人黑色素瘤A375细胞,并显著抑制RhoC mRNA和蛋白质表达。